Stockscreener 앱 받기
1.44%
시간 외 거래:
전일 마감가:
$324.30
열려 있는:
$324.09
하루 거래량:
1.90M
Relative Volume:
0.73
시가총액:
$177.14B
수익:
$35.89B
순이익/손실:
$7.01B
주가수익비율:
25.43
EPS:
12.9352
순현금흐름:
$11.54B
1주 성능:
-3.71%
1개월 성능:
+3.53%
6개월 성능:
+10.75%
1년 성능:
+23.16%
1일 변동 폭
$323.55
$329.20
1주일 범위
$319.79
$341.46
52주 변동 폭
$261.43
$346.38
암젠 Stock (AMGN) Company Profile
명칭
Amgen Inc
전화
(805)447-1000
주소
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
AMGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
328.97 | 174.63B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,073.29 | 964.11B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.55 | 514.75B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
221.89 | 390.15B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
146.16 | 271.72B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
111.01 | 268.70B | 63.90B | 19.05B | 13.05B | 7.5596 |
암젠 Stock (AMGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-05 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-11-24 | 재개 | Truist | Hold |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-03 | 재개 | Raymond James | Mkt Perform |
| 2025-05-20 | 재개 | Guggenheim | Neutral |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2024-09-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-05-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 재개 | Raymond James | Mkt Perform |
| 2024-02-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 업그레이드 | Truist | Hold → Buy |
| 2023-10-20 | 재개 | JP Morgan | Neutral |
| 2023-10-17 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 재개 | BofA Securities | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-04-24 | 재확인 | Oppenheimer | Outperform |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 재확인 | Truist | Buy |
| 2022-11-18 | 개시 | Credit Suisse | Underperform |
| 2022-10-31 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2022-10-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-09 | 재확인 | Barclays | Equal Weight |
| 2022-02-09 | 재확인 | Jefferies | Buy |
| 2022-02-09 | 재확인 | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 재확인 | Oppenheimer | Outperform |
| 2022-02-09 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-09-23 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 개시 | Daiwa Securities | Buy |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | 업그레이드 | Truist | Hold → Buy |
| 2020-10-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | 다운그레이드 | Truist | Buy → Hold |
| 2020-10-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 재개 | Guggenheim | Neutral |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-03-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-17 | 재개 | Morgan Stanley | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-05-23 | 업그레이드 | Citigroup | Neutral → Buy |
모두보기
암젠 주식(AMGN)의 최신 뉴스
Amgen (AMGN) Advances While Market Declines: Some Information for Investors - sharewise.com
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses - Benzinga
Amgen Inc. (NASDAQ:AMGN) Shares Could Be 49% Below Their Intrinsic Value Estimate - Yahoo Finance
Amgen Inc. $AMGN Shares Acquired by Global Wealth Management Investment Advisory Inc. - MarketBeat
Decliners Report: Why Amgen Inc stock could rally in 20252025 Breakouts & Breakdowns & Weekly Top Performers Watchlists - moha.gov.vn
Amgen Growth Story Isn't Tapped Out Yet, Says Goldman - Benzinga
Ro partners with Amgen to study barriers to obesity care, GLP-1 access - marketscreener.com
Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance - FinancialContent
Ro announces research collaboration with Amgen to evaluate real-world GLP-1 coverage - marketscreener.com
Amgen (AMGN) Reveals Promising Results from MariTide Phase 2 Stu - GuruFocus
Amgen Inc. $AMGN Shares Acquired by PKO Investment Management Joint Stock Co - MarketBeat
Nordea Investment Management AB Acquires 22,465 Shares of Amgen Inc. $AMGN - MarketBeat
Trickle of Data On Amgen’s MariTide Hints At Potential Of Lower Maintenance Dosing - Citeline News & Insights
Amgen to announce data on obesity drug MariTide at healthcare conference - WNWN-FM
Amgen Inc. $AMGN Shares Bought by Citizens Financial Group Inc. RI - MarketBeat
Amgen says MariTide helped trial patients maintain weight loss - The Mighty 790 KFGO
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules - BioSpace
Amgen Calls 2026 a “Springboard Year” as CEO Flags Major Data, MariTide Phase 3 Push at JPM Event - MarketBeat
Amgen’s MariTide Patients Maintain Weight Loss for Two Years - Bloomberg.com
Amgen's Maritide: A Breakthrough in Diabetes Management - Devdiscourse
Amgen's MariTide phase 2 study shows 'meaningful' reduction in blood sugar, weight - TradingView — Track All Markets
Key Executive Transition from Amgen (AMGN) to BioMarin - GuruFocus
Amgen Fights Regeneron’s Bid to Pause Eylea Antitrust Claims - Bloomberg Law News
Lobbying Update: $37,500 of AMGEN INC. lobbying was just disclosed - Quiver Quantitative
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Amgen Inc. $AMGN Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Meeder Asset Management Inc. Purchases 27,584 Shares of Amgen Inc. $AMGN - MarketBeat
Tema Etfs LLC Boosts Stock Position in Amgen Inc. $AMGN - MarketBeat
First Horizon Corp Takes Position in Amgen Inc. $AMGN - MarketBeat
Amgen Buys U.K. Biotech Company - Los Angeles Business Journal
How Amgen’s DISCO Oncology Licensing Deal Will Impact Amgen (AMGN) Investors - simplywall.st
Amgen Stock Holds Its Ground: What The Latest Price Action, Ratings and Pipeline Signals Mean For In - AD HOC NEWS
Amgen stock slides into weekend as JPMorgan healthcare conference looms - TechStock²
Nepsis Inc. Cuts Stock Position in Amgen Inc. $AMGN - MarketBeat
Is It Time To Reassess Amgen (AMGN) After Its 28% One Year Share Price Gain? - Yahoo Finance
Amgen to acquire Dark Blue for cancer drug DBT 3757 - BioXconomy
State of Alaska Department of Revenue Sells 3,034 Shares of Amgen Inc. $AMGN - MarketBeat
Oregon Public Employees Retirement Fund Buys 15,172 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Nova R Wealth Inc. - MarketBeat
Amgen (NASDAQ:AMGN) Stock Rating Upgraded by UBS Group - MarketBeat
Amgen Inc. $AMGN Shares Bought by Ferguson Wellman Capital Management Inc. - MarketBeat
Amgen Inc. (NASDAQ:AMGN) aligns with nasdaq composite life sciences - Kalkine Media
Can Amgen Inc. stock rebound after recent weaknessQuarterly Earnings Report & Technical Pattern Based Signals - ulpravda.ru
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know - sharewise.com
How Amgen Inc. stock valuations compare to rivalsWeekly Profit Report & Growth Oriented Trading Recommendations - ulpravda.ru
Amgen (AMGN) Valuation Check After DISCO Oncology Deal And Fresh Analyst Optimism - simplywall.st
Amgen (NASDAQ:AMGN) Price Target Raised to $319.00 at Truist Financial - MarketBeat
Goldman Sachs Adjusts Price Target on Amgen to $403 From $400, Maintains Buy Rating - MarketScreener
Amgen Advances Leukemia Strategy With Completed Blinatumomab Study in Japan - TipRanks
Should Amgen’s (AMGN) Exclusive DISCO Oncology Deal Require Action From Investors? - Yahoo Finance
Amgen acquires British Dark Blue Therapeutics for USD 840m - medwatch.com
암젠 (AMGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.90%
1.22%
자본화:
|
볼륨(24시간):